diabetes — diagnosis, targets, and complications

in review 6 min read Updated 2026-11-19
diabetes — diagnosis, targets, and complications

Diagnose diabetes with FPG ≥7.0, A1C ≥6.5%, 2-h OGTT ≥11.1, or random PG ≥11.1 mmol/L with symptoms (confirm once if asymptomatic). Target A1C ≤7.0% for most adults (relax to 7.1–8.5% in frailty/recurrent severe hypoglycaemia), pair with ABCDE vascular protection, and screen microvascular complications at diagnosis in T2DM and at 5 years in T1DM.

do not miss

Suspected type 1 diabetes (young, lean, rapid weight loss, ketosis) or acute hyperglycaemic crisis: do not use A1C to rule out diabetes (rises too slowly) and do not delay insulin waiting for confirmatory repeat labs → diabetic ketoacidosis — management.


screening, diagnosis, and classification

  • Screening (CTFPHC 2012): calculate risk (CANRISK/FINDRISC) every 3–5 years in adults ≥18; do not routinely screen low/moderate risk; screen high risk q3–5 years with A1C; very high risk annually. (Diabetes Canada recommends screening all adults ≥40 q3 years or earlier with risk factors — CTFPHC is more conservative.)
testprediabetesdiabetescaveats
FPG (≥8 h fast)6.1–6.9 mmol/L (IFG)≥7.0 mmol/Luse FPG + A1C together in older adults
A1C (lab, not POC)6.0–6.4%≥6.5%invalid in suspected T1DM, pregnancy, or altered RBC turnover
2-h PG (75 g OGTT)7.8–11.0 mmol/L (IGT)≥11.1 mmol/Lmost sensitive in older adults and cystic fibrosis
random PG—≥11.1 mmol/Lsingle test diagnostic only if classic osmotic symptoms present
  • Confirmation: symptomatic hyperglycaemia → 1 abnormal test suffices; asymptomatic → repeat confirmatory test (preferring the same test, except an asymptomatic random PG ≥11.1 mmol/L should be confirmed with an alternate test; if two different tests are both above threshold, diagnosis is confirmed; if discordant, repeat the abnormal test).
subtypekey clinical cluesconfirmatory clue
T1DMlean/young (any age), ketosis-prone, rapid progressionanti-GAD / IA-2 / ZnT8 antibodies; low C-peptide
LADAadult onset, initially non-insulin-requiring, progresses to insulin within months–yearsanti-GAD positive; lean or normal BMI
T2DMinsulin resistance, metabolic syndrome, family historyclinical diagnosis
MODY (monogenic)autosomal dominant (>2 generations), onset <25 years, non-obese, no ketosis, negative antibodiesgenetic testing (HNF1A/HNF4A responsive to low-dose SU; GCK mild fasting hyperglycaemia needs no Rx)
pancreatogenic (T3c)chronic pancreatitis, CF, hereditary haemochromatosis, post-pancreatectomyexocrine insufficiency; loss of both insulin and glucagon → brittle hypoglycaemia

A1C confounders

A1C reflects mean glucose over 8–12 weeks (~50% from the last 30 days). Use glucose monitoring (or CGM) when A1C is unreliable:

  • Falsely elevated A1C: iron or B12 deficiency (prolonged RBC lifespan), splenectomy, alcoholism, uraemia (carbamylated Hb), hyperbilirubinaemia.
  • Falsely lowered A1C: haemolysis, acute blood loss, recent transfusion, erythropoietin/iron/B12 replacement (reticulocytosis), splenomegaly, CKD (shortened RBC lifespan), chronic liver disease, hypertriglyceridaemia, dapsone, ribavirin, antiretrovirals.
  • Variable: haemoglobinopathies, HbF.

glycaemic and CGM targets

Check A1C every 3 months until stable at target, then every 6 months.

patient groupA1C targetfasting / preprandial2-h postprandial
most adults (T1DM & T2DM)≤7.0%4.0–7.0 mmol/L (4.0–5.5 if A1C >7% & low hypo risk)5.0–10.0 mmol/L (5.0–8.0 if A1C >7% & low hypo risk)
T2DM, low hypoglycaemia risk (to ↓ CKD/retinopathy)≤6.5% (or <6.0% for remission)——
functionally dependent7.1–8.0% (or <8.0% if not on insulin/SU)5.0–8.0 mmol/L<12.0 mmol/L
frail / dementia / recurrent severe hypo / limited life expectancy7.1–8.5% (or <8.5% if not on insulin/SU)6.0–9.0 mmol/L<14.0 mmol/L
end of lifedo not measure A1Cavoid symptomatic hyperglycaemia and any hypoglycaemia—

CGM metrics (DC 2021)

Require ≥70% sensor wear over 14 days. Every 10% increase in time in range (TIR) ≈ 0.5% decrease in A1C.

metricmost adults (T1DM / T2DM)older / high-risk for hypoglycaemiapregnant T1DM
TIR>70% (3.9–10.0 mmol/L)>50% (3.9–10.0 mmol/L)>70% (3.5–7.8 mmol/L)
TBR<4% (<3.9); <1% (<3.0)<1% (<3.9)<4% (<3.5: <3% 3.1–3.4, <1% <3.0)
TAR<25% (>10.0); <5% (>13.9)<10% (>13.9)<25% (>7.8)

ABCDE vascular protection

  • A — A1C ≤7.0% (early tight control gives legacy CV and microvascular benefit).
  • B — BP <130/80 mmHg (Diabetes Canada; ADA 2026 encourages SBP <120 if high CV/kidney risk and tolerated → hypertension).
  • C — Cholesterol: statin for clinical CVD, age ≥40, age >30 with duration >15 years, or microvascular disease; intensify if LDL ≥2.0 mmol/L (≥1.8 with ASCVD per CCS → dyslipidaemia).
  • D — Drugs for vascular protection:
    • ACEi/ARB (at vascular-protective doses: ramipril 10 mg, perindopril 8 mg, telmisartan 80 mg): clinical CVD, age ≥55 with an additional CV risk factor or end-organ damage, or microvascular disease. Reliable contraception is required when prescribing ACEi, ARB, or statins in patients of childbearing potential.
    • ASA 81–162 mg daily: established CVD (Grade A against routine primary prevention; may consider in selected patients with additional CV risk factors, Grade D; clopidogrel 75 mg if ASA-intolerant).
    • SGLT2i / GLP-1 RA / finerenone: per comorbidity → type 2 diabetes, chronic kidney disease.
  • E — Exercise, healthy eating, and smoking cessation.

microvascular complication screening

complicationwhen to starthow & frequencyfirst-line management
retinopathyT1DM: 5 y post-dx if age ≥15 · T2DM: at diagnosisdilated fundoscopy or retinal photography by optometrist/ophthalmologist · q1y (T1DM), q1–2y (T2DM if none)glycaemic + BP control; fenofibrate (added to statin therapy; not for CVD prevention) slows progression of established T2DM retinopathy (Grade A); anti-VEGF / laser / vitrectomy for sight-threatening disease
nephropathyT1DM: 5 y post-dx · T2DM: at diagnosisannual random urine ACR + eGFR (positive if ACR >20 or ≥2 of 3 >2 mg/mmol, or eGFR <60)max tolerated RASi + SGLT2i ± finerenone / semaglutide → chronic kidney disease
neuropathyT1DM: 5 y post-pubertal · T2DM: at diagnosisannual 10 g monofilament or 128 Hz vibration at dorsum of great toeoptimise glycaemia; painful neuropathy: pregabalin (Grade A), gabapentin, duloxetine, amitriptyline, or venlafaxine; topical nitrate spray; opioids last resort
foot careall patientsannual exam (neuropathy, pulses/PAD, skin/callus, deformity); more often if high riskfitted footwear, prompt offloading + sharp debridement + moist wound care for ulcers; total contact cast for acute Charcot foot; vascular assessment → peripheral arterial disease
diabetic autonomic neuropathy

Screen clinically for orthostatic hypotension (SBP drop >20 mmHg), resting tachycardia, gastroparesis, overflow bladder, and erectile dysfunction — cardiac autonomic neuropathy independently predicts mortality.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+7 more sources

Suggest a correction diabetes — diagnosis, targets, and complications